Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: A review

Inflammatory Bowel Diseases

Volumn 17, Issue 8, 2011, Pages 1814-1821

  Linares, Pablo M ^a   Gisbert, Javier P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Crohn's disease; growth factors; inflammatory bowel disease; lymphangiogenesis; lymphangiogenic factors; ulcerative colitis

Indexed keywords

ADIPOCYTOKINE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR; PODOPLANIN; SCATTER FACTOR; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADIPOSE TISSUE; ANGIOGENESIS; CONTROLLED STUDY; DISEASE EXACERBATION; ENTERITIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; ULCERATIVE COLITIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79960222244     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21554     Document Type: Review

References (76)

1. Avraamides CJ, Garmy-Susini B, Varner JA., Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008; 8: 604-617.
2. Hatoum OA, Heidemann J, Binion DG., The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci. 2006; 1072: 78-97. (Pubitemid 44448445)
3. Pousa ID, Gisbert JP, Mate J,. [Vascular development in inflammatory bowel disease.] Gastroenterol Hepatol. 2006; 29: 414-421. (Pubitemid 44386357)
4. Pousa ID, Mate J, Gisbert JP., Angiogenesis in inflammatory bowel disease. Eur J Clin Invest. 2008; 38: 73-81. (Pubitemid 351143416)
5. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001; 96: 822-828. (Pubitemid 32240738)
6. Kenney BC, Jain D., Identification of lymphatics within the colonic lamina propria in inflammation and neoplasia using the monoclonal antibody D2-40. Yale J Biol Med. 2008; 81: 103-113.
7. Kaiserling E, Krober S, Geleff S., Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology. 2003; 36: 52-61. (Pubitemid 36900181)
8. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003; 162: 575-586. (Pubitemid 36267864)
9. Cueni LN, Detmar M., New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006; 126: 2167-2177. (Pubitemid 44413162)
10. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005; 166: 913-921. (Pubitemid 40315647)
11. Geleff S, Schoppmann SF, Oberhuber G., Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. 2003; 442: 231-237. (Pubitemid 36399216)
12. Fogt F, Pascha TL, Zhang PJ, et al. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int J Mol Med. 2004; 13: 211-214.
13. Pedica F, Ligorio C, Tonelli P, et al. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 2008; 452: 57-63.
14. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995; 92: 3566-3570.
15. Kubo H, Cao R, Brakenhielm E, et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A. 2002; 99: 8868-8873. (Pubitemid 34693650)
16. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000; 14: 2087-2096.
17. Partanen TA, Alitalo K, Miettinen M., Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999; 86: 2406-2412. (Pubitemid 30010384)
18. Paavonen K, Puolakkainen P, Jussila L, et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol. 2000; 156: 1499-1504. (Pubitemid 30646689)
19. Ran S, Volk L, Hall K, et al. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. 2010; 17: 229-251.
20. Chen YN, Gu Y., Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer. Chin J Cancer. 2009; 28: 1337-1343.
21. Flister MJ, Wilber A, Hall KL, et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood. 2010; 115: 418-429.
22. de la Torre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer. 2006; 13: 931-944. (Pubitemid 44763268)
23. Zhang QH, Qian K, Li XJ, et al. [Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2007; 10: 212-216.
24. Lohela M, Helotera H, Haiko P, et al. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol. 2008; 173: 1891-1901.
25. Onimaru M, Yonemitsu Y, Fujii T, et al. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. Am J Physiol Heart Circ Physiol. 2009; 297: H1685-1696.
26. Lahdenranta J, Hagendoorn J, Padera TP, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009; 69: 2801-2808.
27. White JD, Hewett PW, Kosuge D, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002; 62: 1669-1675. (Pubitemid 34408487)
28. Guo R, Zhou Q, Proulx ST, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009; 60: 2666-2676.
29. Beck PL, Podolsky DK., Growth factors in inflammatory bowel disease. Inflamm Bowel Dis. 1999; 5: 44-60.
30. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983-985.
31. Cao R, Eriksson A, Kubo H, et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004; 94: 664-670. (Pubitemid 38387750)
32. Pousa ID, Gisbert JP., Gastric angiogenesis and Helicobacter pylori infection. Rev Esp Enferm Dig. 2006; 98: 527-541. (Pubitemid 350104421)
33. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005; 201: 1089-1099. (Pubitemid 40524677)
34. Pousa ID, Mate J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis. 2008; 14: 61-67. (Pubitemid 351196870)
35. Cimpean AM, Seclaman E, Ceausu R, et al. VEGF-A/HGF induce Prox-1 expression in the chick embryo chorioallantoic membrane lymphatic vasculature. Clin Exp Med. 2010; 10: 169-172.
36. Goebel S, Huang M, Davis WC, et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G648-654.
37. Griga T, Tromm A, Spranger J, et al. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998; 33: 504-508. (Pubitemid 28277250)
38. Azzam N., Angiogenesis and inflammatory bowel disease. Saudi J Gastroenterol. 2007; 13: 37-38.
39. Duenas Pousa I, Mate Jimenez J, Salcedo Mora X, et al. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol Hepatol. 2007; 30: 518-524.
40. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136: 585 -595 e585.
41. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003; 18: 418-422. (Pubitemid 37062733)
42. Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004; 49: 1265-1274. (Pubitemid 39178099)
43. Griga T, Gutzeit A, Sommerkamp C, et al. Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999; 11: 175-179. (Pubitemid 29103579)
44. Griga T, Werner S, Koller M, et al. Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes. Dig Dis Sci. 1999; 44: 1196-1201. (Pubitemid 29297228)
45. Griga T, Voigt E, Gretzer B, et al. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 1999; 46: 920-923. (Pubitemid 29224765)
46. Griga T, May B, Pfisterer O, et al. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 2002; 49: 116-123. (Pubitemid 34289498)
47. Hanabata N, Sasaki Y, Tanaka M, et al. Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis. Scand J Gastroenterol. 2005; 40: 188-193. (Pubitemid 40188999)
48. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 573-577. (Pubitemid 39276464)
49. Schaffler A, Furst A, Buchler C, et al. Vascular endothelial growth factor secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease. J Gastroenterol Hepatol. 2006; 21: 1419-1423. (Pubitemid 44154710)
50. Ando Y, Inaba M, Sakaguchi Y, et al. Subcutaneous adipose tissue-derived stem cells facilitate colonic mucosal recovery from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. Inflamm Bowel Dis. 2008; 14: 826-838. (Pubitemid 351898068)
51. Beddy D, Watson RW, Fitzpatrick JM, et al. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg. 2004; 91: 72-77. (Pubitemid 38122053)
52. Taha Y, Raab Y, Larsson A, et al. Vascular endothelial growth factor (VEGF)-a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci. 2004; 49: 109-115. (Pubitemid 38183754)
53. Shin JW, Min M, Larrieu-Lahargue F, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell. 2006; 17: 576-584. (Pubitemid 43191094)
54. Nakao S, Maruyama K, Zandi S, et al. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J. 2010; 24: 504-513.
55. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004; 101: 11658-11663. (Pubitemid 39095352)
56. Matsuo M, Yamada S, Koizumi K, et al. Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur J Cancer. 2007; 43: 1748-1754. (Pubitemid 47042372)
57. Bousvaros A, Zurakowski D, Fishman SJ, et al. Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing. Dig Dis Sci. 1997; 42: 378-386. (Pubitemid 27112987)
58. Thorn M, Raab Y, Larsson A, et al. Intestinal mucosal secretion of basic fibroblast growth factor in patients with ulcerative colitis. Scand J Gastroenterol. 2000; 35: 408-412. (Pubitemid 30304425)
59. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004; 6: 333-345. (Pubitemid 39361435)
60. Cao Y., Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle. 2005; 4: 228-230. (Pubitemid 41365322)
61. Krzystek-Korpacka M, Neubauer K, Matusiewicz M., Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem. 2009; 42: 1602-1609.
62. Kumagai S, Ohtani H, Nagai T, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001; 195: 21-33. (Pubitemid 34036883)
63. Jiang WG, Davies G, Martin TA, et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 2005; 16: 723-728.
64. Cao R, Bjorndahl MA, Gallego MI, et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood. 2006; 107: 3531-3536.
65. Kajiya K, Hirakawa S, Ma B, et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005; 24: 2885-2895. (Pubitemid 43079892)
66. Srivastava M, Zurakowski D, Cheifetz P, et al. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 548-553. (Pubitemid 33151848)
67. Thatch KA, Mendelson KG, Haber MM, et al. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease. J Surg Res. 2009; 156: 245-249.
68. Ido A, Numata M, Kodama M, et al. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol. 2005; 40: 925-931. (Pubitemid 41662515)
69. Huang Z, Bao SD., Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol. 2004; 10: 463-470. (Pubitemid 38325297)
70. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002; 3: 411-423.
71. Morisada T, Oike Y, Yamada Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005; 105: 4649-4656. (Pubitemid 40807284)
72. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55-60. (Pubitemid 27450643)
73. Nguyen VP, Chen SH, Trinh J, et al. Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2. BMC Cell Biol. 2007; 8: 10.
74. Ganta VC, Cromer W, Mills GL, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis. 2010; 16: 1029-1039.
75. Koutroubakis IE, Xidakis C, Karmiris K, et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest. 2006; 36: 127-132.
76. Chidlow JH, Jr., Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G5-G18. (Pubitemid 47105158)